ClinicalTrials.gg
CompletedNCT01382901Updated Feb 20, 2018Results posted

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

A Phase 2 interventional study of Ferric Carboxymaltose (FCM) and Placebo in Restless Legs Syndrome (RLS), sponsored by American Regent, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)

02

Conditions studied

  • Restless Legs Syndrome (RLS)
03

In context

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

This study's enrollment of 45 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.

Browse Restless Legs Syndrome studies →

Lead sponsor

American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.

First submitted after American Regent, Inc. became part of Daiichi Sankyo.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects > or = to 18 years old, and able to give to the study.
  • RLS signs and symptoms affirming diagnosis. The IRLS Diagnostic Criteria for RLS must be met.
  • Subjects have RLS symptoms > or = to 5 nights per week for at least the past 3 months.
  • A baseline score > or = to 15 on the IRLS Rating Scale.
  • At least one leg with an average baseline Periodic Leg Movement while asleep (PLMS) > or = to 15 movements per hour and at least 3 days of baseline PLMS data is measurable in each leg.
  • Subjects on anti-depressants, sleep medications, dopamine agonists, benzodiazepines, narcotics or other RLS treatments must be off therapy at least one week or 5 half lives, whichever is longer before any baseline RLS assessments and PLM measurements are obtained.
  • Subject has regular sleep hours between 9 p.m. and 9 a.m.
  • Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of .

Exclusion criteria

Exclusion Criteria:

  • RLS 2° to other CNS disease or injury. Such disorders include peripheral neuropathy, neurodegenerative disorders, and multiple sclerosis.
  • RLS 2° to Chronic Kidney Disease.
  • Any pain related or sleep related disorders (e.g. sleep apnea) which may confound the outcome measures.
  • History of neuroleptic akathisia.
  • Oral iron use (including multivitamins with iron) after screening.
  • Parenteral iron use within 4 weeks prior to screening.
  • Parenteral iron use > 125 mg per week within 4 to 8 weeks prior to screening.
  • History of > or = to 10 blood transfusions in the past 2 years.
  • Anticipated need for blood transfusion during the study.
  • Known reaction to any component to FCM.
  • Previously participated in an FCM clinical trial.
  • Chronic or serious active severe infection.
  • (other than basal or squamous cell skin cancer or the subject has been cancer free for > 5 years).
  • Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).
  • Receiving prescription medication for the treatment of bronchospasm.
  • Pregnant or lactating women.
  • Severe peripheral vascular disease with significant skin changes.
  • Seizure disorder currently being treated with medication.
  • Baseline ferritin > 300 ng/mL.
  • Baseline TSAT > or = to 45%.
  • History of hemochromatosis or hemosiderosis or other iron storage disorders.
  • or ALT greater than the .
  • greater than the upper limit of normal.
  • Calcium or phosphorous outside the normal range.
  • Known positive antigen (HBsAg) or viral antibody (HCV) with evidence of active hepatitis.
  • Known positive -1/HIV-2 antibodies (anti-HIV).
  • Received an drug within 30 days before randomization.
  • Chronic alcohol or drug abuse within the past 6 months.
  • Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure (New York Heart Association) III or IV, or poorly controlled hypertension according to the judgment of the investigator.
  • Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.
  • Subject unable to comply with study requirements.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Intravenous (IV) Iron

    Drug: Ferric Carboxymaltose (FCM)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. International Restless Legs Syndrome (IRLS) Total Score

    The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.

    Time frame: Change from Baseline to Day 28

07

Results

Posted Jun 27, 2011

Participant flow

Study Period: March 23, 2006 to July 16, 2007 Locations: Hospitals and Medical Clinics (15 total sites)

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM) 2 x 500 mgPlacebo
Started2421
Completed77
Not completed1714

Outcome measures

PrimaryInternational Restless Legs Syndrome (IRLS) Total Score

The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.

Time frame:
Change from Baseline to Day 28
Reported as:
Mean · Scores on a scale
International Restless Legs Syndrome (IRLS) Total Score
Scores on a scaleFerric Carboxymaltose (FCM) 2 x 500 mgPlacebo
International Restless Legs Syndrome (IRLS) Total Score-8.9 ± 8.52-4.0 ± 0.040

Adverse events

Collected over 1 year and 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM) 2 x 500 mg—0/24 (0%)9/24 (37.5%)
Placebo—0/21 (0%)6/21 (28.6%)
Most frequent other events
Most frequent other events
EventFerric Carboxymaltose (FCM) 2 x 500 mgPlacebo
DiarrheaGastrointestinal disorders3/240/21
Blood phosphorus decreasedInvestigations3/240/21
HeadacheNervous system disorders2/242/21
Back PainMusculoskeletal and connective tissue disorders1/242/21
InsomniaPsychiatric disorders0/242/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM) 2 x 500 mgPlaceboTotal
<=18 years000
Between 18 and 65 years201535
>=65 years4610
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM) 2 x 500 mgPlaceboTotal
Mean49.5 ± 11.4254.1 ± 13.6851.7 ± 12.59
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM) 2 x 500 mgPlaceboTotal
Female171128
Male71017
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM) 2 x 500 mgPlaceboTotal
United States242145
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2011
First posted
Jun 27, 2011
Start
Mar 2006
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Results first posted
Jun 27, 2011
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01382901
First posted
Jun 27, 2011
Start date
Mar 2006
Primary completion
Jul 2007
Completion
Jul 2007
Results posted
Jun 27, 2011
Last update
Feb 20, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion